['gastroparesis', 'diabetes mellitus']
['prucalopride', 'placebo']

        Inclusion Criteria:

          -  Age of 18-64 years

          -  Existing clinical diagnosis of gastroparesis for at least one year as judged by the
             study gastroenterologist based on past medical history, clinical symptoms

          -  Sufficiently symptomatic at time of proposed study (Minimum baseline postprandial
             satiety/fullness subscale of the Gastroparesis Cardinal Symptoms Index (GCSI) score of
             1.5 or higher)

          -  Delayed gastric emptying (>10% retention at 4 hours) on standard solid meal
             scintigraphic emptying study within the previous year

          -  Normal upper endoscopy (with the exception of small bezoars) since the onset of
             symptoms

          -  If female of childbearing potential, a negative urine pregnancy test administered
             between consent and screening appointments

          -  Able to provide written informed consent

        Exclusion Criteria:

          -  Clinical evidence (including physical exam and/or ECG) of significant cardiovascular,
             respiratory, renal, hepatic, gastrointestinal, hematological, neurological,
             psychiatric or other disease that may interfere with the objectives of the study
             and/or pose safety concerns, including pregnancy or breastfeeding.

          -  Study entry ECG showing second or third degree heart block, left bundle branch block
             (LBBB) or acute ischemic changes

          -  Blood electrolytes (Na, K, CL) measured within past 6 months outside of normal
             reference ranges (except during an acute gastroparesis flare-up)

          -  Use of narcotics or promotility agents which cannot be stopped prior to study entry.

          -  Use of tricyclic antidepressants (at doses exceeding 25 mg/day) and/or macrolide
             antibiotics. (Stable doses of SSRI/SNRI antidepressants and/or non-macrolide
             antibiotics are permitted)

          -  Laxative use that cannot be stopped prior to the start of the study

          -  Participated in clinical trial with motility agents within past 30 days

          -  History of gastrointestinal surgery excepting appendectomy and/or cholecystectomy in
             the past, or any other major surgeries within 3 months

          -  Estimated GFR<30 measured within past 6 months.

          -  History of cardiovascular disorder including myocardial infarction, pacemaker or
             implanted defibrillator, or history of life-threatening arrhythmia
      